JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

JNJ

229.87

+1.14%↑

UNH

370.84

+0.14%↑

TMO

478.44

+2.91%↑

ISRG

457.44

+1.12%↑

ABT

90.76

-0.82%↓

Search

Inmode Ltd

Chiusa

SettoreSettore sanitario

14.41 3.3

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.96

Massimo

14.44

Metriche Chiave

By Trading Economics

Entrata

5.2M

27M

Vendite

11M

104M

P/E

Media del settore

10.007

67.147

Margine di Profitto

26.022

Dipendenti

660

EBITDA

5.7M

31M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+21.78% upside

Dividendi

By Dow Jones

Utili prossimi

6 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-120M

907M

Apertura precedente

11.11

Chiusura precedente

14.41

Notizie sul Sentiment di mercato

By Acuity

50%

50%

186 / 347 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Inmode Ltd Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

30 apr 2026, 23:08 UTC

Utili

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 23:07 UTC

Utili

Australia's Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 22:20 UTC

Utili

Australia's ANZ Raises 1st Half Profit 9%, Warns of Coming Iran Impacts

30 apr 2026, 23:48 UTC

Discorsi di Mercato

Nikkei May Rise After Gains on Wall Street -- Market Talk

30 apr 2026, 23:47 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

30 apr 2026, 23:47 UTC

Discorsi di Mercato

Coles's Earnings Views Likely to Edge Down Despite Positives -- Market Talk

30 apr 2026, 23:27 UTC

Discorsi di Mercato

Liontown Lithium Recovery Expected to Improve -- Market Talk

30 apr 2026, 23:22 UTC

Utili

Apple's Incoming CEO John Ternus Makes Appearance as Company Bests Expectations -- Update

30 apr 2026, 23:20 UTC

Discorsi di Mercato

Wildcat Resources Stands Out Among Lithium Developers -- Market Talk

30 apr 2026, 22:52 UTC

Utili

Australia's ANZ Warns of Coming Iran Impacts as First-Half Profit Rises -- Update

30 apr 2026, 22:33 UTC

Utili

Zhejiang Expressway: Impairment Loss Weighed on Net >0576.HK

30 apr 2026, 22:32 UTC

Utili

Zhejiang Expressway 1Q Net CNY1.31B Vs. Net CNY1.48B >0576.HK

30 apr 2026, 22:32 UTC

Utili

Zhejiang Expressway 1Q Rev CNY5.32B Vs. CNY4.36B >0576.HK

30 apr 2026, 22:24 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Also Reflects Time Needed to Implement Corporate Restructure For JV

30 apr 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Revised Timetable Reflects Time Needed to Get Regulatory Approvals

30 apr 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Now Expects Deal to Complete in 1H FY2027

30 apr 2026, 22:23 UTC

Acquisizioni, Fusioni, Takeovers

Mineral Resources: Executes Key Formal Agreements With Posco on Stake Sale

30 apr 2026, 22:11 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

30 apr 2026, 22:11 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

30 apr 2026, 22:11 UTC

Discorsi di Mercato

Apple Says Demand for Lower-Cost Laptop is Off the Charts -- Market Talk

30 apr 2026, 22:05 UTC

Utili

Australia's ANZ Raises 1H Profit 9%, Warns of Coming Iran Impacts

30 apr 2026, 21:57 UTC

Utili

ANZ CEO: Increase in Collective Provisions Reflects Risk>ANZ.AU

30 apr 2026, 21:56 UTC

Utili

ANZ CEO: Minimal Impact on ANZ's Credit, Capital, Liquidity>ANZ.AU

30 apr 2026, 21:56 UTC

Utili

ANZ CEO: No Material Increase in New Cases of Household Hardship>ANZ.AU

30 apr 2026, 21:55 UTC

Utili

ANZ CEO: Households Entered Crisis With Generally Strong Balance Sheets>ANZ.AU

30 apr 2026, 21:54 UTC

Utili

ANZ CEO: No Material Change in Overall Corporate Borrowing Behavior >ANZ.AU

30 apr 2026, 21:54 UTC

Utili

ANZ CEO: Corporate Customers Have Been Building Capital, Liquidity Against Shocks>ANZ.AU

30 apr 2026, 21:53 UTC

Utili

ANZ CEO: Much of Iran Conflict's Potential Impact Remains Ahead>ANZ.AU

30 apr 2026, 21:49 UTC

Utili

ANZ Group 1H Total Operating Income A$11.20B Vs. A$10.995B>ANZ.AU

30 apr 2026, 21:49 UTC

Utili

ANZ Group 1H Customer Deposits A$770.7B Vs. A$756.6B>ANZ.AU

Confronto tra pari

Modifica del prezzo

Inmode Ltd Previsione

Obiettivo di Prezzo

By TipRanks

21.78% in crescita

Previsioni per 12 mesi

Media 17 USD  21.78%

Alto 21 USD

Basso 15 USD

Basato su 6 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Inmode Ltd - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

6 ratings

1

Acquista

5

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

14.1 / 14.44Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Strong Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

186 / 347 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Inmode Ltd

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was incorporated in 2008 and is headquartered in Yokne'am, Israel.
help-icon Live chat